Gilead Sciences exercised its option to exclusively license Kymera Therapeutics’ KT-200, an oral CDK2 molecular glue degrader candidate. The move follows a strategic collaboration in which Gilead previously paid Kymera for an option and then advanced to an exclusive license after preclinical data package delivery. KT-200 is designed to degrade CDK2 rather than inhibit kinases through traditional small-molecule binding, which Kymera says aims to improve selectivity and reduce dose-limiting toxicities associated with CDK1 inhibition. Gilead will run IND-enabling studies with an eye toward filing to test in humans. The deal adds to a flurry of oncology-focused “protein degrader” licensing and strengthens the competitive set across targeted degradation modalities. It also reinforces CDK2 as a continued oncology target as companies seek next-generation cell-cycle control strategies. For biotech leaders, this is a clear example of how big pharma continues to acquire preclinical differentiation when regulatory pathways remain uncertain in later stages, using option-to-license structures to manage risk.